GlassScriptPhysician profile
John M Lazaro
NPI 1649238684
$3,081.51
in general payments reported to CMS, 2019-2025
26 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2023: $643 · 2024: $1,104 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,836.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $431.02 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $401.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $355.55 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $272.27 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $213.52 | 2023-2025 | |
| Pfizer INC. | $162.97 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $149.73 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.43 | 2023-2025 | Xifaxan, Trulance |
| Abbvie INC. | $113.15 | 2024-2025 | |
| Abbott Laboratories | $109.50 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $84.64 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $83.80 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $70.10 | 2024-2025 | Korlym |
| Lundbeck LLC | $65.95 | 2024-2025 | Vyepti, Rexulti |
| Insulet Corporation | $65.94 | 2024 | Omnipod |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.38 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $45.62 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $44.45 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $43.53 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.08 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $39.33 | 2023 | |
| Xeris Pharmaceuticals, INC. | $32.09 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $28.95 | 2023 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $20.71 | 2023 | Injectafer |
| Azurity Pharmaceuticals, INC. | $16.46 | 2025 | Alvesco |
| Esperion Therapeutics, INC. | $16.08 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lazaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.